weight gain on glp 1 November Blog weight gain on glp 1
Description
Classify the Patients Response: Excellent responder: 10% or more body-weight loss by 612 months
The gastrointestinal adverse events associated with GLP-1 receptor agonists are typically dose-dependent, transient, and manageable with slow titration (Meier, Diabetes, Obesity and Metabolism )
10.1038/nm1196-1254 109 SecherA.JelsingJ.BaqueroA
An uncommon case of dulaglutide-related morbilliform drug eruption
Semaglutide may be the right starting point if you: Are new to GLP-1 therapy and want to start with the most established option Have a moderate amount of weight to lose Don't have significant insulin resistance or type 2 diabetes Want a well-documented safety profile with years of real-world data Tirzepatide may be the stronger option if you: Have a higher BMI or significant amount of weight to lose Have insulin resistance, prediabetes, or type 2 diabetes Have tried Semaglutide previously with limited results Want the most aggressive metabolic intervention currently available Are dealing with significant visceral fat or metabolic syndrome The Most Important Factor: Medical Guidance The right medication is the one your provider determines is appropriate for your health history, labs, BMI, and goals not the one that sounds more advanced or that someone else is using
Longer wear does not increase benefits
